![]() The one-time treatments won't come cheap. In data Kite released in February, the company found that out of 101 patients, 36% had a complete response to the treatment after six months. In November, Kite is expected to get an answer from the FDA regarding its CAR-T treatment for a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. Gilead won't have to wait long to see if the FDA will approve Kite's leading cell therapy, which is called axicabtagene ciloleucel or axi-cel. One of the panelists called it "most exciting thing I've seen in my lifetime." The FDA is expected to decide whether to approve that therapy, a treatment for pediatric acute lymphoblastic lymphoblastic leukemia, by October. In July, a Food and Drug Administration panel voted in favor of approving one of these treatments made by Novartis. That means that a person's own cells are the therapy, which makes it more difficult to manufacture than your average pill. Short for chimeric antigen receptor T-cell therapy, CAR-T treatment removes a person's cells from the body, reengineers them, and then puts the cells back in the body, where they can attack cancer cells. "We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer." Here's why cell therapies could be game-changing "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients," Gilead CEO John Milligan said in a news release. It's a form of cancer immunotherapy - or a therapy that harnesses the body's immune system to take on cancer cells.įor Gilead, which is known for its HIV and hepatitis C medications, this is an entirely new area of cancer development. Adimab enables its partners to rapidly expand their biologics pipelines through a broad array of technology access arrangements.The drugmaker's therapy that's a few months away from a possible approval is a highly personalized cancer treatments called CAR T-cell therapy. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies and bispecifics that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. About AdimabĪdimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human lgGs. In addition, Adimab has transferred its platform for broad use to GSK, Biogen and Novo Nordisk. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Sanofi and others. Over the past 5+ years, Adimab has established funded discovery collaborations with over 30 companies. Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic CAR product sales that are optioned under the agreement. Kite will also have the option to exclusively license antibodies for development and commercialization as therapeutic CAR products. For each target, the agreement grants Kite the right to research antibodies generated during the collaboration for potential use in therapeutic CAR-T products. Kite and Adimab have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against selected targets. “Kite is focused on finding partnerships, such as this collaboration with Adimab, that help us establish a competitive advantage in the CAR-T space,” said Margo Roberts, Ph.D., Chief Scientific Officer of Kite. “Our platform can rapidly deliver a diverse panel of antibodies with varying affinities and ultra-high selectivity.” “Kite has established itself as a leader in the field of engineered autologous cell therapies, and we are excited to have the opportunity to work with them,” said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. ![]() Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite. Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a new collaboration with Kite Pharma, Inc., (Nasdaq:KITE).
0 Comments
Leave a Reply. |